Ephion Health
PrivateLast Round
Grant
Nov 30, 2023
Est. Valuation
$3.06M
Total Funding Raised
$1.46M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ephion Health operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Grant round in November 2023.
Ephion Health is a healthcare technology company that has developed a platform to monitor patient functional capacity using data from wearables and AI-powered algorithms to generate digital biomarkers for use in clinical trials and patient care.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Medical AI, Health IoT, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ephion Health Comparables
Compare Ephion Health with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Koneksa Health | 77% | |
| VivoSense | 77% | |
| Great Lakes NeuroTechnologies Inc. | 77% |
For institutional investors. Book with your work email.
Ephion Health Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 30, 2023 | ||||
| Seed | Oct 2, 2023 | ||||
| Seed | Jun 5, 2023 | ||||
| Grant | Feb 15, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ephion Health Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agencia Estatal de Investigación | Grant |
| Brain VC Fund | Seed |
| Center for Technological Development and Innovation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 176% MoM.
- Aug 29, 2025
Developing an AI platform for digital biomarkers using third-party wearables.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 5, 2026
Ephion develops a digital biomarker that captures patient mobility by transforming wearable-sensor data into objective indicators for measuring disease progression, assessing real-world treatment responses, and preventing risks such as falls in older adults; the technology already has CE marking.
For institutional investors. Book with your work email.
Ephion Health Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ephion Health's valuation, stock price, and market status.
Is Ephion Health a public or private company?
Ephion Health is a private company.
What is the current stock price of Ephion Health?
Ephion Health is a private company, so its shares have no public market price. Caplight tracks Ephion Health's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ephion Health worth (valuation)?
Ephion Health's valuation is estimated at $3.1M based on funding round data.
Can I buy Ephion Health stock?
Ephion Health shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ephion Health's last funding round?
Ephion Health's most recent funding round was Grant on November 30, 2023.
Who are the main investors in Ephion Health?
Key investors in Ephion Health include Brain VC Fund.
Will Ephion Health IPO soon?
No public IPO plans have been announced for Ephion Health.
How can I track Ephion Health secondary market activity?
Caplight tracks bids, offers, and trades in Ephion Health's shares on secondary markets.